It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Conventional dendritic cells (cDC) play key roles in immune induction, but what drives their heterogeneity and functional specialization is still ill-defined. Here we show that cDC-specific deletion of the transcriptional repressor Bcl6 in mice alters the phenotype and transcriptome of cDC1 and cDC2, while their lineage identity is preserved. Bcl6-deficient cDC1 are diminished in the periphery but maintain their ability to cross-present antigen to CD8+ T cells, confirming general maintenance of this subset. Surprisingly, the absence of Bcl6 in cDC causes a complete loss of Notch2-dependent cDC2 in the spleen and intestinal lamina propria. DC-targeted Bcl6-deficient mice induced fewer T follicular helper cells despite a profound impact on T follicular regulatory cells in response to immunization and mounted diminished Th17 immunity to Citrobacter rodentium in the colon. Our findings establish Bcl6 as an essential transcription factor for subsets of cDC and add to our understanding of the transcriptional landscape underlying cDC heterogeneity.
Conventional dendritic cells are playing a pivotal role at the interface of innate and adaptive immunity, but they are a heterogenous group regarding function and regulation. Here, the authors show that although Bcl6-deficiency does not regulate general DC subset identity, Bcl6 expression is required for a specific subset of type 2 DCs in mice, resulting in impaired T helper cell responses and further clarifying molecular players driving DC subset heterogeneity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Technical University of Denmark (DTU), Section for Experimental and Translational Immunology, Institute for Health Technology, Kongens, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870)
2 University of Bonn, Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
3 LMU Munich, Institute for Immunology, Biomedical Center, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
4 Ludwig-Maximillians-Universität München, Biomedical Center, Institute of Cardiovascular Physiology and Pathophysiology, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); LMU Munich, Walter-Brendel-Centre of Experimental Medicine, University Hospital, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
5 Lund University, Cell Reprogramming in Hematopoiesis and Immunity Laboratory, Lund Stem Cell Center, Molecular Medicine and Gene Therapy, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Lund University, Wallenberg Center for Molecular Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
6 University of Bonn, Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); LMU Munich, Institute for Immunology, Biomedical Center, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
7 Technical University of Denmark (DTU), Section for Experimental and Translational Immunology, Institute for Health Technology, Kongens, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870); University of Calgary, Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
8 University of Bonn, Quantitative Systems Biology, Life and Medical Sciences (LIMES) Institute, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
9 Lund University, Cell Reprogramming in Hematopoiesis and Immunity Laboratory, Lund Stem Cell Center, Molecular Medicine and Gene Therapy, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Lund University, Wallenberg Center for Molecular Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); University of Coimbra, Center for Neuroscience and Cell Biology, Coimbra, Portugal (GRID:grid.8051.c) (ISNI:0000 0000 9511 4342)
10 Technical University of Denmark (DTU), Section for Experimental and Translational Immunology, Institute for Health Technology, Kongens, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870); University of Calgary, Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Lund University, Immunology Section, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)